CompagOs
H├╝nenberg · Founded 2023
About CompagOs
Our mission is to help oncologists select the most effective treatment for patients with cancer in the bone. Leveraging 3D bioprinting technology, we recreate the unique cancerous condition of the patient's bone in a controlled laboratory environment, enabling us to assess different drug reactions and determine personalized treatment options. By surpassing the limitations of conventional animal and 2D models, we also envision our solution as a powerful tool for drug development, accurately reproducing human physiological conditions and driving innovation in the field. Together, we aim to revolutionize cancer treatment by offering personalized solutions that improve patient outcomes and advance the field of oncology.
Company Facts
- Founded: 2023
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $282.9K
- Last round: Convertible Note (Sep 2024)
- Website: https://www.compagos.ch
Industries & Categories
Oncology
Social Profiles
Canonical: https://fsome.com/organization/compagos-173949 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.